ABSTRACT BACKGROUND There is no effective medical treatment for heart failure with preserved ejection fraction (HFpEF).
designed to improve symptoms and outcome in HFpEF.
Numerous lines of evidence indicate that abnormalities in nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling play a central role in causing these reserve limitations (11) (12) (13) . Organic nitrates can improve NO-cGMP signaling but may be limited by the development of tolerance or symptomatic hypotension (14, 15) . Indeed, 1 factor complicating HFpEF treatment is that the hemodynamic perturbations causing symptoms are often absent at rest but observed only during physiological stresses, such as exercise (2) .
Inorganic nitrite is now recognized as an alternative in vivo source of NO-cGMP that is independent of the traditional NO synthase pathway (16) (17) (18) (19) . Intriguingly, the reduction of nitrite to bioactive NO may be enhanced by tissue hypoxia and acidosis (19) , which develop during exercise. This suggests that nitrite might more selectively target hemodynamic derangements developing during stress in people with HFpEF (2,10), with less risk of hypotension at rest (15) .
The current study tests the hypothesis that, compared with placebo, acute infusion of sodium nitrite would improve exercise hemodynamics and enhance cardiac reserve in patients with HFpEF.
METHODS
This double-blind, randomized, placebo-controlled, parallel-group trial was designed to study the effects of intravenous sodium nitrite on cardiovascular hemodynamics at rest and during exercise in subjects with HFpEF. Patients referred to the Mayo Clinic cardiac catheterization laboratory for invasive hemodynamic exercise stress testing were enrolled.
Written informed consent was provided by all subjects before participation in study-related procedures. The Mayo Clinic Institutional Review Board approved the study.
STUDY POPULATION AND PROTOCOL. HFpEF was defined by clinical symptoms of chronic heart failure (dyspnea, fatigue), normal ejection fraction ($50%), and increased left heart filling pressures (pulmonary capillary wedge pressure [PCWP] ) at rest (>15 mm Hg) and/or with exercise ($25 mm Hg) (1, 2) . Exclusion criteria included significant valvular heart disease (>mild stenosis, >moderate regurgitation), cor pulmonale, significant pulmonary disease, congenital heart disease, glucose 6-phosphate dehydrogenase deficiency, left-to-right shunt, unstable coronary artery disease, myocardial infarction within 60 days, hypertrophic or infiltrative cardiomyopathy, primary renal or hepatic disease, high-output heart failure, or constrictive pericarditis.
Subjects receiving long-term treatment with organic nitrates or phosphodiesterase 5 inhibitors also were excluded.
Subjects were studied on their long-term medications in the post-absorptive state and supine position. Cardiac catheterization was performed with simultaneous expired gas analysis at rest and during supine exercise at a 20-W workload for 5 min, as previously described (2, 8) . After the first exercise phase (before any drug administration) and after return to steadystate baseline hemodynamic values, subjects were randomized 1:1 to infusion of placebo (normal saline solution) or sodium nitrite (50 mg/ kg/min) (Hope Pharmaceuticals, Scottsdale, Arizona) for 5 min. The nitrite/placebo infusions were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of infusion content. After 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 5 min, identical to the study's first phase. Arterial and venous blood samples and hemodynamic and expired gas data were acquired during each stage of the protocol.
Right heart catheterization was performed through a 9-F sheath via the internal jugular vein. Transducers were zeroed at mid-axilla. Right atrial pressure (RAP), pulmonary artery (PA) pressure, and PCWP were measured at end-expiration (mean of $3 beats) using 2-F, high-fidelity micromanometer-tipped catheters (Millar Instruments, Houston, Texas) advanced through the lumen of a 7-F, fluid-filled catheter (Arrow, Teleflex, Morrisville, North Carolina) (2, 8) .
Mean RAP and PCWP were taken at mid A wave. Arterial blood pressure (BP) was measured continuously through a 4-to 6-F radial arterial cannula.
Oxygen consumption (VO 2 ) was measured from expired gas analysis (MedGraphics, St. Paul, Minnesota) taken as the average from the 60 s preceding arterial and mixed venous blood sampling (8) . Ventilatory efficiency was assessed by the increase in minute ventilation relative to carbon dioxide production (V E /VCO 2 ). Central venous and arterial blood samples were obtained during each stage to measure the methemoglobin level and blood gases. Plasma nitrite concentrations were assessed in the final 6 subjects enrolled in the trial using a liquid chromatographyfluorometric assay (BASi, West Lafayette, Indiana) as previously described (20 
RESULTS
A total of 28 subjects were enrolled in the trial between January and September 2014. Baseline characteristics were not significantly different between treatment groups ( Table 1) . Subjects were older, obese, and predominantly female, with a high prevalence of hypertension. On average, subjects displayed normal LV chamber size and mass, left atrial enlargement, mild LV diastolic dysfunction, and increased N-terminal pro-B-type natriuretic peptide levels ( Table 1) .
At rest, subjects were hypertensive, with slightly increased right and left heart filling pressures, mild pulmonary hypertension, slightly increased PVR, and normal CO ( Table 2) . With exercise, participants displayed significant increases in heart rate, BP, CO, VO 2 , and CaO 2 À CvO 2 . Mean RAP and PCWP increased dramatically during exercise, with secondary increase in PA pressures. Pulmonary vasodilation was impaired during exercise, manifest by lack of a decrease in PVR and acute decreases in PA compliance compared with rest ( Table 2) . V E /VCO 2 slope was increased (37 AE 5), consistent with marked ventilatory inefficiency during exercise.
The increase in CO relative to metabolic demand (DCO/DVO 2 slope) in the HFpEF subjects was 4.7 AE 2.7 ml/ml. Most participants (75%) displayed an abnormal DCO/DVO 2 slope (defined as <6 ml/ml) (21), indicating significant limitation in CO reserve during Nitrite had no effect on exercise heart rate or systolic BP, but it tended to reduce mean BP during exercise more than placebo (p ¼ 0.05) ( Table 4) . Nitrite decreased exercise RAP and PA pressure compared with placebo ( Figure 2 , Table 4 ). The nitrite-mediated decrease in exercise PA pressure was exclusively due to lowering of the PCWP, as there was no effect on exercise PVR or PA compliance. Nitrite tended to reduce V E /VCO 2 slope compared with placebo (À0 AE 2 vs. þ1 AE 3; p ¼ 0.2). 2C and 2D ).
By design, the external workload performed during exercise was equivalent before and after study drug infusion (20 W), but despite this, nitrite slightly increased the VO 2 achieved at 20 W compared with placebo ( Table 4) ; this VO 2 increase was coupled to greater enhancement in exercise CO ( Figure 3A) , with no change in CaO 2 À CvO 2 compared with to placebo (Table 4) . Nitrite infusion increased the DCO/DVO 2 slope compared with placebo (þ2.1 AE 2.2 ml/ml vs. þ0.3 AE 1.7 ml/ml; p ¼ 0.025) to a mean value that falls within the normal range for humans without heart failure (dotted line, Figure 3B ), indicating an improvement in CO reserve relative to metabolic demand.
The increase in exercise CO with nitrite was caused exclusively by greater enhancement in SV ( Figure 3C ), as there was no effect on exercise heart rate ( Table 4) .
Although the enhanced SV reserve with nitrite might have been related in part to systemic vasodilation (lower SVR), importantly, there was also a greater increase in LV stroke work with nitrite ( Figure 3D) , indicating an acute increase in LV systolic performance, independent of changes in cardiac loading (23) .
PLASMA NITRITE LEVELS. Venous plasma nitrite levels were obtained in 4 subjects randomized to Values are mean AE SD. *Columns show rest-exercise hemodynamics before study drug infusion in subjects randomized to placebo or nitrite. All between-group comparisons at rest and with exercise are p ¼ not significant. †p < 0.0001 versus baseline, within-subject change. ‡p # 0.05 versus baseline, within-subject change.
BP ¼ blood pressure; CaO2 À CvO2 ¼ arteriovenous O2 content difference; CO ¼ cardiac output; DSC ¼ dyne/ s•cm 5 ; LVSW ¼ left ventricular stroke work; PA ¼ pulmonary artery; PCWP ¼ pulmonary capillary wedge pressure; PVR ¼ pulmonary vascular resistance; RA ¼ right atrial; SVR ¼ systemic vascular resistance; VO2 ¼ oxygen consumption; W ¼ watt. Abbreviations as in Table 2 . However, elegant work from van Heerebeek et al. (12) showed that cGMP limitation in HFpEF is not related to excessive breakdown but rather inadequate production, suggesting that NO-cGMP-providing therapies may be the more effective approach. A major barrier in managing many patients with HFpEF is related to the fact that the increase in cardiac filling pressures and PA pressure is confined to exercise, whereas hemodynamics at rest may be more normal (1) (2) (3) (4) (5) (6) (7) (8) . Thus, an agent that enhances NO-cGMP signaling preferentially during exercise would be expected to provide more targeted hemodynamic improvements precisely at the time of greatest need.
THE NITRATE-NITRITE-NO PATHWAY IN HEART
FAILURE. Inorganic nitrite and nitrate were previously considered to be inert byproducts of NO metabolism, but recent work has shown these serve as an important in vivo reservoir of NO (16) (17) (18) (19) .
Dietary nitrate is absorbed, secreted in saliva, and then converted by oral bacteria to nitrite, which is absorbed and then reduced by a number of enzymes, including deoxygenated hemoglobin or myoglobin, to NO (19, 28, 29) . This reaction is believed to be enhanced in the setting of hypoxia and acidosis, which develop in the tissues and venous circulation during exercise, potentially allowing for hypoxic vasodilation that complements the alternative oxygen-dependent NO synthase pathway (16, 18, 19) .
In contrast to the organic nitrates that require aldehyde dehydrogenase and other enzymes for activation (14), there is no tolerance with nitrate-nitrite (17).
The greater reduction in SVR with exercise in the current study is consistent with previously described vasodilatory effects in humans, and the fact that Nitrite Improves Exercise Hemodynamics in HFpEF in SVR) (30) . The improvement in CO reserve observed with nitrate therapy was due to a greater increase in heart rate, with no significant effect on SV.
The current invasive hemodynamic data extend the noninvasive findings of Zamani et al. (30) ,
showing greater increases in CO and improved systemic vasodilation with nitrite in HFpEF subjects, assessed using gold-standard techniques. The increase in CO noted in the current study greatly exceeded the small increase in VO 2 , indicating an acute increase in the ability of the heart to provide blood flow relative to metabolic needs (CO/VO 2 slope), which has been shown to be impaired on average in HFpEF (10) . In contrast to Zamani et al. (30) , the enhanced CO reserve observed in the current study was related to a greater increase in SV with exercise, with no effect on rest or exercise heart rate.
Although the greater increase in SV in the current study was likely mediated in part by improved afterload reduction, we also observed beneficial effects of nitrite on ventricular performance, assessed by the greater increase in LV stroke work with exercise.
Stroke work is independent of afterload, but varies directly with preload (end-diastolic volume) (23).
Therefore, we cannot determine whether the beneficial effect of nitrite on LV performance in the current study was mediated by improvements in diastolic reserve (greater increase in end-diastolic volume despite lower filling pressures), systolic reserve (increased contractility), or both. However, given the fact that both diastolic and systolic reserves are known to contribute to the pathophysiology of HFpEF, the observation of a direct myocardial benefit from nitrite is an important observation.
The main novel finding and primary endpoint of the trial was the greater reduction in PCWP during exercise, a key force mediating symptoms of exertional dyspnea in people with HFpEF. The magnitude of decrease in exercise PCWP with nitrite was much greater than the resting PCWP, consistent with greater Plasma nitrite levels were assessed in a minority of subjects, including 4 randomized to nitrite and 2 to placebo. Levels were below assay at rest in all subjects and after study drug infusion in those receiving placebo. This is consistent with the low level of plasma nitrite levels in humans under normal circumstances (0.05 to 0.3 mM) (19) . In subjects receiving active drug, a marked increase in plasma nitrite to 
